Medical device firm Theragen has received the U.S. Patent for the development of ActaStim-S Spine Fusion Bone Growth Stimulator system.

ActaStim-S is a new spine fusion stimulator that combines modern design, a data-rich digital health platform, and scientifically tested therapeutic stimulation.

The system encourages patient recovery, compliance, involvement, and informed conversation with healthcare professionals during the crucial and drawn-out post-operative fusion phase.

Theragen CEO Chris McAuliffe said: “Spinal fusion is a healing process, often characterized as a race to achieve solid fusion before failure of the implanted hardware.

“Electrical stimulation is a clinically proven, safe and effective post-operative adjunct therapy that can help patients win that race, however, its clinical effectiveness requires regular use over several months.”

“That’s why we’ve taken a user-centric approach, designing a more wearable device that also offers a digital health component that gives patients the unique opportunity to engage in, follow, and truly impact their own recovery.”

The company develops and manufactures non-invasive, electrical stimulation DME products to offer therapeutic energy for healing and empower patients and play an active role in their recovery.

Theragen COO, VP of R&D Richard Pearce said: “The system includes a remarkably discreet, unobtrusive wearable unit that is very well received by patients.

“It includes utilisation tracking, onboard activity sensing, Bluetooth smartphone connectivity, and an intuitive app that helps patients visualise their progress over time.”

“The essence of this new U.S. Patent (#11,394,919) is focused on ensuring that this connectivity does not interfere with ease of use — and that data collection and transfer can happen quickly and effectively.”